Femasys Expands FemSperm(TM) Product Line with New Insemination Prep Kit to Broaden Gynecology-Based Access to FemaSeed®

Stock Information for PharmaCyte Biotech Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About PharmaCyte Biotech Inc.

PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment
Femasys Announces Third Quarter Financial Results for 2025
Femasys Advances Global Growth with Second Partner Order for FemBloc® in Europe
Femasys Secures FDA Approval to Advance Final FemBloc® Trial Phase and $12 Million Financing, with Potential to Reach $58 Million
Femasys Announces Initiation of Post-Market Surveillance Study for FemBloc® Permanent Birth Control in Europe
Femasys to Exhibit at the ASRM 2025 Scientific Congress & Expo
Femasys Accelerates European Growth for FemBloc® with Kebomed Partnership
Femasys Partners with Medical Electronic Systems to Launch FemSperm(TM) Analysis Kit for use with FemaSeed

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.